LEERINK
CENTER FOR PHARMACOECONOMICS

Value Estimates for Innovative Lipid-Lowering Therapeutics in ASCVD



Published on: October 30, 2025

> Substantial health system and societal value remains for further reductions in cardiovascular events and mortality

In this Center for Pharmacoeconomics (CPE) Exclusive, we compare the impacts of an innovative lipid-lowering therapy used as an adjunct to statin therapy to statin therapy alone across a range of cost-effectiveness frameworks and assumptions.

Purpose of Report: Reducing cardiovascular events such as heart attacks and stroke can offer substantial value to patients, the health system, and society. Even considering the effectiveness of statins in reducing these events, unmet need exists to address suboptimal cholesterol levels and the residual risk of cardiovascular events. In this report, we evaluate some of the quantifiable health system and societal impacts of innovative lipid-lowering therapies that may further reduce these cardiovascular events.

Summary of Findings: An innovative lipid-lowering therapy that further reduces major adverse cardiovascular events by 20-30% could produce a lifetime societal benefit in the range of $79,000-$122,000 per person treated and a value-informed price in the range of $5,000-$21,000 per year at a cost-effectiveness threshold recently suggested by the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. These estimates may be conservative.

Key Considerations: The estimates are sensitive to a number of factors, including the model structure, time horizon, perspective, population, effectiveness and safety of the therapy, rates of events under standard therapy, and the cost-effectiveness threshold. Different plausible assumptions would generate different plausible estimates.

Interpreting the Findings: Read the report to see how the estimates vary by the effectiveness of the treatment, the cost-effectiveness framework used, and the cost-effectiveness threshold assumed. We do not provide these estimates to suggest a price for an innovative therapeutic, but rather to estimate some of the quantifiable health system and societal value, identify key drivers of health system and societal efficiency, suggest “novel” value elements that may influence the value proposition, and provide a reference point for how a product might perform under different cost-effectiveness analysis frameworks and assumptions. This may be useful to companies as they are thinking about evidence generation.

To discuss a specific innovative therapeutic in ASCVD with the Leerink Center for Pharmacoeconomics, please contact your Leerink representative.

Read our full report for more details and discussion.

The Leerink Center for Pharmacoeconomics is a division of MEDACorp and an affiliate of Leerink Partners

Leerink Center for Pharmacoeconomics

- Melanie Whittington, PhD, Managing Director, Head of the Center for Pharmacoeconomics

Contributors:

Melanie Whittington

Center for Pharmacoeconomics

Disclosures:

This information (including, but not limited to, prices, quotes, and statistics) has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and the information and any opinions contained herein are as of the date of this material and the Firm does not undertake any obligation to update them. The information is not an offer to sell or a solicitation to buy any product to which this information relates. Leerink Partners LLC ("Firm"), its officers, directors, employees, proprietary accounts, and affiliates may have a position, long or short, in the securities referred to in this report, and/or other related securities, and from time to time may increase or decrease the position or express a view that is contrary to that contained in this piece. The Firm's research analysts, bankers, salespeople, and traders may provide oral or written market commentary or trading strategies that are contrary to opinions expressed, and the Firm's market making desk may make investment decisions that are inconsistent with the opinions expressed in this document. The past performance of securities does not guarantee or predict future performance. This material does not take into account individual circumstances, objectives, or needs and is not intended as a recommendation to any particular person(s). As such, the financial instruments discussed herein may not be suitable for all investors, and investors must make their own investment decisions based upon their specific investment objectives and financial situation. This material is a marketing communication and is not and should not be construed as investment research or a research report prepared by a research analyst. Any views portrayed in this material may differ from those of the research department of Leerink Partners LLC. All information contained herein is intended solely for your own personal, informational use, and you are not permitted to reproduce, retransmit, disseminate, sell, license, distribute, republish, broadcast, post, circulate or commercially exploit the information in any manner or media without the express written consent of Leerink Partners LLC, or to use the information for any unlawful purpose. Additional information is available upon request by contacting the Editorial Department, Leerink Partners LLC, 53 State Street, 40th Floor, Boston, MA 02109.MEDACorp LLC (MEDACorp), an affiliate of Leerink Partners LLC, is a global network of independent healthcare professionals (Key Opinion Leaders and consultants) providing industry and market insights to Leerink Partners and its clients.© 2024 Leerink Partners LLC. All Rights Reserved.
Member FINRA/SIPC